Last reviewed · How we verify
A Phase III Extended Clinical Trial of Long-term Safety and Efficacy of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis
To observe the safety and effectiveness of long-term use of jaktinib hydrochloride tablets in the treatment of moderate and severe atopic dermatitis
Details
| Lead sponsor | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
|---|---|
| Phase | Phase 3 |
| Status | UNKNOWN |
| Enrolment | 400 |
| Start date | 2023-01-11 |
| Completion | 2024-12 |
Conditions
- Atopic Dermatitis
Interventions
- Jaktinib Hydrochloride Tablet
Primary outcomes
- Number and percentage of subjects with treatment emergent adverse event (TEAE) — 36 weeks after the first dose
Safety of the drug - Number and percentage of subjects with Serious Adverse Event (SAE) — 36 weeks after the first dose
Safety of the drug
Countries
China